Company Overview
Integris Medtech Ltd, incorporated in 2008, is a diversified global MedTech company operating across cardiovascular devices, clinical diagnostics, and scientific laboratory solutions. The company follows an integrated model encompassing development, manufacturing, and commercialisation.
It maintains a manufacturing footprint in India, Germany, and the Netherlands, supplying products to over 65 countries. Its customer network includes 9,500+ laboratories and 2,000+ hospitals and cathlabs.
The business is split between an Asia-focused laboratory/hospital segment and a Europe-centric cardiovascular segment with proprietary brands such as Chrome and Protégé. As of June 2025, the workforce stood at 1,879 employees supporting global operations and clinical trial activities across 100+ sites.
Business Model
The revenue model relies on selling a vast portfolio of 22,000+ SKUs across 200+ brands to both public and private healthcare institutions. Revenue streams are geographically diversified with strong presence in India, Europe, and Southeast Asia, alongside Rest of World markets.
The company operates two core divisions: one serving laboratories and hospitals in Asia and another focusing on cardiovascular products in Europe. Customer concentration risk appears mitigated by a large base of 11,500+ institutional accounts.
However, dependency on proprietary cardiovascular brands in Europe and regulatory approvals across multiple jurisdictions creates operational execution dependencies.
Industry Context
The global medical devices and diagnostics industry is driven by aging populations, rising chronic disease prevalence, and increasing healthcare expenditure in emerging markets. India's MedTech sector benefits from government initiatives like PLI schemes and Ayushman Bharat.
The cardiovascular segment sees innovation in minimally invasive procedures, while diagnostics demand grows with preventive healthcare trends. Competitive pressures are intense from large global MNCs (Medtronic, Abbott, Siemens) and domestic players (Poly Medicure, Meril Life).
Regulatory hurdles (MDR in EU, CDSCO in India) and pricing pressure in public procurement pose challenges. Integris's multi-geography manufacturing and broad SKU portfolio position it as a mid-sized diversified player.
Issue Details & Capital Structure
The IPO comprises a Fresh Issue of ₹600 crore with no Offer for Sale (OFS) component indicated, meaning all proceeds flow to the company for general corporate purposes and business expansion. The price band is yet to be announced.
The issue is scheduled to open on November 27, 2026, and close on December 1, 2026, on the Mainboard of NSE and BSE. Lot size and minimum retail investment will be determined post price band finalisation.
Absence of OFS signals promoter confidence and ensures capital directly fuels growth and debt reduction, as suggested by the sharp borrowing decline between March and June 2025.
Bidding Schedule & Lot Sizes
The IPO bidding window is scheduled from November 27, 2026, to December 1, 2026. Basis of allotment is expected around December 4, 2026, with refunds/unblocking by December 5, 2026, and demat credit by December 8, 2026.
Tentative listing date is December 9, 2026, on NSE and BSE. Since the price band is unannounced, the minimum retail lot investment (typically ₹14,000-₹15,000) cannot be calculated yet.
Retail investors should monitor the RHP for final price band, lot size, and anchor investor allocation details. The 3-day bidding window is standard for mainboard issues.
Financial Performance & Margins
Financials show consistent revenue growth: ₹1,369.66 Cr (FY23) → ₹1,582.26 Cr (FY24) → ₹1,959.58 Cr (FY25). EBITDA improved from ₹168.82 Cr (FY23) to ₹309.40 Cr (FY25), with margins expanding from 12.3% to 15.8%.
PAT turned positive in FY25 at ₹70.68 Cr after losses of ₹40.54 Cr (FY23) and ₹4.88 Cr (FY24). The Q1 FY26 (Jun'25) PAT of ₹267.57 Cr is anomalously high versus the full prior year, warranting scrutiny for one-time items.
Net Worth surged to ₹3,889.99 Cr (Jun'25) from ₹2,752.52 Cr (Mar'25), while borrowings fell sharply to ₹793.42 Cr from ₹1,729.46 Cr, indicating deleveraging via fresh equity.
| Period Ended | 30 Jun 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 4,019.62 | 3,641.34 | 2,989.20 | 2,553.87 |
| Total Income | 508.93 | 1,959.58 | 1,582.26 | 1,369.66 |
| Profit After Tax | 267.57 | 70.68 | -4.88 | -40.54 |
| EBITDA | 78.73 | 309.40 | 190.45 | 168.82 |
| NET Worth | 3,889.99 | 2,752.52 | 2,681.02 | 2,629.52 |
| Reserves and Surplus | 2,299.84 | 1,150.74 | 1,135.71 | 1,073.12 |
| Total Borrowing | 793.42 | 1,729.46 | 813.10 | 556.54 |
Peer Valuation & Industry Comparison
Key listed peers in the diversified MedTech/diagnostics space include Poly Medicure, Meril Life Sciences (recently listed), Trivitron Healthcare (unlisted), and global giants like Siemens Healthineers (listed via parent). Integris differentiates with a unique dual focus on cardiovascular devices (proprietary EU brands) and laboratory diagnostics, alongside multi-country manufacturing.
Revenue scale (~₹1,960 Cr FY25) places it in the mid-tier. Poly Medicure (FY24 Rev ~₹1,100 Cr) is smaller but pure-play; Meril is larger (~₹3,000 Cr+).
Integris's EBITDA margin (~16%) is competitive. However, lack of OFS and high promoter holding via foreign entities contrasts with typical Indian promoter-led structures.
Valuation benchmarks will depend on the undisclosed price band.
Promoters & Corporate Governance
Promoters include Singapore-based entities Evercure Holdings Pte. Ltd. and Medicore Holdings Pte.
Ltd., alongside individual promoters Gurmit Singh Chugh and Punita Sharma. The foreign promoter structure suggests potential private equity or strategic investor backing prior to listing.
The leadership team manages complex multi-jurisdictional operations across three manufacturing sites and 65+ markets. Corporate governance will be tested post-listing given the cross-border holding structure; investors should scrutinise related-party transactions and board independence in the RHP.
The sharp increase in Net Worth and Reserves by June 2025 indicates recent equity infusion, likely linked to pre-IPO rounds involving these entities.